Fahimeh Faqihi
Research Subjects
Fahimeh Faqihi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Lucinda Notley-McRobb
Macquarie Medical School, Faculty of Medicine, Health, and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia
3 shared publications - Marcus Andrew Stoodley
Macquarie Medical School, Faculty of Medicine, Health, and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia
3 shared publications - Bradley A. Edwards
School of Psychological Sciences, Monash University, Melbourne, Australia
1 shared publication Christina Naidoo
Department of Respiratory and Sleep Medicine, Westmead Hospital , Sydney
1 shared publication- David William Inglis
School of Engineering Macquarie University Sydney New South Wales Australia
1 shared publication - Denise M. O'DRiscoll
The Ritchie Centre, Monash Institute of Medical Research, Monash University, Victoria, Australia
1 shared publication
Latest Publications
- 11 September 2026
- Published by Oxford University Press (OUP) in SLEEP
Hypoxic burden from obstructive sleep apnea is increased in Pacific Islanders with distinct pathophysiological traits
Study Objectives: Obstructive sleep apnea (OSA) is common in Pacific Islanders; however, its pathophysiological mechanisms are unknown. We compared OSA severity and endotypes between Pacific Islanders and Caucasians. Materials and Methods: Retrospective polysomnography data were analyzed using inverse probability of treatment weighting (IPTW) to balance age, sex, and BMI. Sleep stage endotypes were derived using validated non-invasive methods. Generalized linear models (GLMs) were used to estimate population-average differences and rank-based tests used as sensitivity analyses. Results: Forty two Pacific Islanders vs 62 Caucasians were included. There was no difference in apnea–hypopnea index between groups (adjusted mean difference 2.8 events/h, 95% CI [−9.0 to 14.5]; p = .64). Pacific Islanders had higher mean apnea length (5.6 s, [2.1 to 8.9]; p = .001), oxygen desaturation index ≥3% (12.5 events/h, [4.3 to 20.7]; p = .003), average desaturation during events (2.4%, [1.1 to 4.0]; p < .001), time with SpO₂ < 90% (12.3 min, [2.5 to 22.0]; p = .016), hypoxic burden (67.4% min/h, [21.7 to 113.2]; p = .012) and supine proportion (20.8% [6.6 to 34.9], pGLM = 0.005). They also had higher rapid eye movement (REM) arousal threshold (14.4%Veupnea, [1.3 to 27.5]; p = .033), lower REM Vpassive (−13.3%Veupnea, [−23.8 to −2.9]; p = .015), and higher non-rapid eye movement (NREM) loop gain (0.04, [0.00 to 0.09]; p = .047), except for REM arousal threshold endotype differences were absent after supine adjustment. Conclusions: In Pacific Islanders, OSA is characterized by longer apnea and increased hypoxic burden, with distinct endotypes. Strategies targeting endotypes and hypoxic burden may improve treatment and mitigate cardiometabolic consequences in this population.
- 11 September 2026
- Published by Oxford University Press (OUP) in SLEEP
Hypoxic burden from obstructive sleep apnea is increased in Pacific Islanders with distinct pathophysiological traits
Study Objectives: Obstructive sleep apnea (OSA) is common in Pacific Islanders; however, its pathophysiological mechanisms are unknown. We compared OSA severity and endotypes between Pacific Islanders and Caucasians. Materials and Methods: Retrospective polysomnography data were analyzed using inverse probability of treatment weighting (IPTW) to balance age, sex, and BMI. Sleep stage endotypes were derived using validated non-invasive methods. Generalized linear models (GLMs) were used to estimate population-average differences and rank-based tests used as sensitivity analyses. Results: Forty two Pacific Islanders vs 62 Caucasians were included. There was no difference in apnea–hypopnea index between groups (adjusted mean difference 2.8 events/h, 95% CI [−9.0 to 14.5]; p = .64). Pacific Islanders had higher mean apnea length (5.6 s, [2.1 to 8.9]; p = .001), oxygen desaturation index ≥3% (12.5 events/h, [4.3 to 20.7]; p = .003), average desaturation during events (2.4%, [1.1 to 4.0]; p < .001), time with SpO₂ < 90% (12.3 min, [2.5 to 22.0]; p = .016), hypoxic burden (67.4% min/h, [21.7 to 113.2]; p = .012) and supine proportion (20.8% [6.6 to 34.9], pGLM = 0.005). They also had higher rapid eye movement (REM) arousal threshold (14.4%Veupnea, [1.3 to 27.5]; p = .033), lower REM Vpassive (−13.3%Veupnea, [−23.8 to −2.9]; p = .015), and higher non-rapid eye movement (NREM) loop gain (0.04, [0.00 to 0.09]; p = .047), except for REM arousal threshold endotype differences were absent after supine adjustment. Conclusions: In Pacific Islanders, OSA is characterized by longer apnea and increased hypoxic burden, with distinct endotypes. Strategies targeting endotypes and hypoxic burden may improve treatment and mitigate cardiometabolic consequences in this population.
- Open Access
- 2 October 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (10) , 305
A Simple Model to Study Mosaic Gene Expression in 3D Endothelial Spheroids
Aims: The goal of this study was to establish a simple model of 3D endothelial spheroids with mosaic gene expression using adeno-associated virus (AAV) transduction, with a future aim being to study the activity of post-zygotic mutations common to vascular malformations. Methods: In this study, 96-well U-bottom plates coated with a commercial repellent were seeded with two immortalized human endothelial cell lines and aggregation monitored using standard microscopy or live-cell analysis. The eGFP expression was used to monitor the AAV transduction. Results: HUVEC-TERT2 could not form spheroids spontaneously. The inclusion of collagen I in the growth medium could stimulate cell aggregation; however, these spheroids were not stable. In contrast, the hCMEC/D3 cells aggregated spontaneously and formed reproducible, robust 3D spheroids within 3 days, growing steadily for at least 4 weeks without the need for media refreshment. The hCMEC/D3 spheroids spontaneously developed a basement membrane, including collagen I, and expressed endothelial-specific CD31 at the spheroid surface. Serotypes AAV1 and AAV2QUADYF transduced these spheroids without toxicity and established sustained, mosaic eGFP expression. Conclusions: In the future, this simple approach to endothelial spheroid formation combined with live-cell imaging could be used to rapidly assess the 3D phenotypes and drug and radiation sensitivities arising from mosaic mutations common to brain vascular malformations.
- 2 October 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (10) , 305
Open AccessA Simple Model to Study Mosaic Gene Expression in 3D Endothelial Spheroids
Aims: The goal of this study was to establish a simple model of 3D endothelial spheroids with mosaic gene expression using adeno-associated virus (AAV) transduction, with a future aim being to study the activity of post-zygotic mutations common to vascular malformations. Methods: In this study, 96-well U-bottom plates coated with a commercial repellent were seeded with two immortalized human endothelial cell lines and aggregation monitored using standard microscopy or live-cell analysis. The eGFP expression was used to monitor the AAV transduction. Results: HUVEC-TERT2 could not form spheroids spontaneously. The inclusion of collagen I in the growth medium could stimulate cell aggregation; however, these spheroids were not stable. In contrast, the hCMEC/D3 cells aggregated spontaneously and formed reproducible, robust 3D spheroids within 3 days, growing steadily for at least 4 weeks without the need for media refreshment. The hCMEC/D3 spheroids spontaneously developed a basement membrane, including collagen I, and expressed endothelial-specific CD31 at the spheroid surface. Serotypes AAV1 and AAV2QUADYF transduced these spheroids without toxicity and established sustained, mosaic eGFP expression. Conclusions: In the future, this simple approach to endothelial spheroid formation combined with live-cell imaging could be used to rapidly assess the 3D phenotypes and drug and radiation sensitivities arising from mosaic mutations common to brain vascular malformations.
- Open Access
- 4 July 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (7) , 776
The Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations
In cardiovascular and cerebrovascular biology, control of thrombosis and the coagulation cascade in ischemic stroke, myocardial infarction, and other coagulopathies is the focus of significant research around the world. Ischemic stroke remains one of the largest causes of death and disability in developed countries. Preventing thrombosis and protecting vessel patency is the primary goal. However, utilization of the body’s natural coagulation cascades as an approach for targeted destruction of abnormal, disease-associated vessels and tissues has been increasing over the last 30 years. This vascular targeting approach, often termed “vascular infarction”, describes the deliberate, targeted delivery of a thrombogenic effector to diseased blood vessels with the aim to induce localized activation of the coagulation cascade and stable thrombus formation, leading to vessel occlusion and ablation. As systemic delivery of pro-thrombotic agents may cause consternation amongst traditional stroke researchers, proponents of the approach must suitably establish both efficacy and safety to take this field forward. In this review, we describe the evolution of this field and, with a focus on thrombogenic effectors, summarize the current literature with respect to emerging trends in “coaguligand” development, in targeted tumor vessel destruction, and in expansion of the approach to the treatment of brain vascular malformations.
- 4 July 2021
- Published by MDPI AG in Biomedicines
- Vol. 9 (7) , 776
Open AccessThe Evolution of Safe and Effective Coaguligands for Vascular Targeting and Precision Thrombosis of Solid Tumors and Vascular Malformations
In cardiovascular and cerebrovascular biology, control of thrombosis and the coagulation cascade in ischemic stroke, myocardial infarction, and other coagulopathies is the focus of significant research around the world. Ischemic stroke remains one of the largest causes of death and disability in developed countries. Preventing thrombosis and protecting vessel patency is the primary goal. However, utilization of the body’s natural coagulation cascades as an approach for targeted destruction of abnormal, disease-associated vessels and tissues has been increasing over the last 30 years. This vascular targeting approach, often termed “vascular infarction”, describes the deliberate, targeted delivery of a thrombogenic effector to diseased blood vessels with the aim to induce localized activation of the coagulation cascade and stable thrombus formation, leading to vessel occlusion and ablation. As systemic delivery of pro-thrombotic agents may cause consternation amongst traditional stroke researchers, proponents of the approach must suitably establish both efficacy and safety to take this field forward. In this review, we describe the evolution of this field and, with a focus on thrombogenic effectors, summarize the current literature with respect to emerging trends in “coaguligand” development, in targeted tumor vessel destruction, and in expansion of the approach to the treatment of brain vascular malformations.